Active or untreated CNS metastases; history of pneumonitis, autoimmune or chronic viral diseases; previous treatment with docetaxel, CD137 agonists, anti-CTLA4, anti-PD L1, or anti-PD-1 therapeutic antibodies, or PD-1/PD-L1 pathway-targeting agents. The gene discussed is TNFRSF9; the disease is pneumonitis.